Skip to main content

Clinical Trial AI: Maintaining Data Integrity with Audit-Grade Logging

Clinical trial teams are starting to use AI for monitoring summaries, protocol deviation triage, adverse-event narrative drafting, and site communication support. The opportunity is real, but so is the integrity problem: if you cannot reconstruct what data was sent, which controls fired, how the provider was selected, and why a response was accepted or rejected, then the workflow is not truly reviewable. Keeptrusts gives you a practical control boundary with rbac, data-routing-policy, pii-detector, hipaa-phi-detector, healthcare-compliance, quality-scorer, and audit-logger, plus the platform event stream and export features that make those decisions inspectable later.

Use this page when​

  • You are applying AI to clinical operations, study monitoring, adverse-event summaries, or protocol review.
  • You need to preserve subject confidentiality while keeping outputs traceable.
  • You want to describe audit evidence accurately instead of over-claiming what one policy block enforces.

Primary audience​

  • Primary: Technical Leaders
  • Secondary: Technical Engineers, Quality and compliance reviewers

The problem​

Clinical trials create a difficult mix of structured rigor and messy text. Teams work with subject identifiers, visit notes, adverse-event narratives, lab summaries, monitoring observations, protocol amendments, and investigator messages. AI can accelerate all of that, but it also multiplies the number of places where the organization can lose control over the record of how a conclusion was produced.

The risk is not only exposure of participant information. It is also weak traceability. A coordinator pastes a deviation note into a general assistant. The assistant returns a polished summary. Later, a reviewer wants to know whether the model saw raw subject IDs, whether the route was limited to compliant providers, whether the output met the team's minimum quality bar, and whether the resulting text can be tied back to the route configuration in force that day. If the answers are scattered across application logs, browser telemetry, and provider dashboards, the workflow is not fit for a regulated environment.

This is where accuracy matters. The audit-logger policy itself is intentionally minimal in the current implementation: it marks that audit logging is active in the chain and always allows. The broader evidence story comes from the platform's decision events, exports, and storage paths, not from unsupported policy-local retention flags. That nuance is important because "audit-grade" should mean you can reproduce route decisions with the actual platform evidence, not that a single YAML key somehow guarantees GxP readiness by itself.

Clinical trial AI also has a content-integrity problem. A short, vague, or overconfident summary can be worse than no summary because it looks polished enough to slip into an operations workflow. That is why quality gating matters alongside redaction and logging. The right question is not just "did the route protect data?" but also "did the route reject weak output before someone treated it as record-worthy?"

The solution​

The most defensible pattern is to treat trial AI as a governed route with three layers.

The first layer is confidentiality. pii-detector can redact general identifiers and custom research identifiers using detect_patterns, while hipaa-phi-detector adds PHI-oriented heuristics for human subject data. That combination is particularly useful when trial workflows include both standard healthcare identifiers and study-specific tokens.

The second layer is provider control. data-routing-policy does not inspect the prompt itself; it filters declared provider targets using their data_policy metadata. That means you can require zero retention, in-memory processing, tokenized-input support, and no internet egress before the route ever selects a target. For trial operations, that is often more valuable than a general statement that vendors are "approved."

The third layer is output integrity. quality-scorer can reject thin or under-specified responses through minimum-length checks, benchmark toggles, assertions, and failure handling. That is where you protect the workflow from summaries that sound authoritative but fail the team's bar for completeness or traceability. healthcare-compliance then gives you a simple way to prevent the route from drifting into direct treatment advice when the route is supposed to support study operations rather than clinical care.

The foundational healthcare references are already documented in Healthcare (HIPAA), Healthcare (EU GDPR), HIPAA PHI Detector, Healthcare Compliance, and Secure Healthcare AI. The clinical-trial-specific extension is to use those controls as an integrity and evidence boundary, not only a privacy boundary.

Implementation​

This route redacts participant identifiers, limits routing to compliant targets, rejects weak summaries, and marks the decision stream as audited.

pack:
  name: clinical-trial-integrity
  version: 1.0.0
  enabled: true

providers:
  targets:
    - id: local-gxp-review
      provider: ollama
      model: llama3.1:70b
      base_url: http://localhost:11434
      data_policy:
        zero_data_retention: true
        training_opt_out: true
        retention_days: 0
        in_memory_only: true
        sanitized: true
        accepts_tokenized_input: true
        allow_internet_egress: false
        local_only_processing: true

policies:
  chain:
    - rbac
    - data-routing-policy
    - pii-detector
    - hipaa-phi-detector
    - healthcare-compliance
    - quality-scorer
    - audit-logger

policy:
  rbac:
    deny_if_missing:
      - X-Org-ID
      - X-User-ID
      - X-User-Role
    roles:
      study-monitor:
        allowed_tools:
          - summarize
          - extract_findings
      qa-reviewer:
        allowed_tools:
          - "*"
    data_access:
      study-monitor:
        max_sensitivity: confidential
      qa-reviewer:
        max_sensitivity: restricted
    minimum_necessary:
      enabled: true
      allowed_phi_roles:
        - study-monitor
        - qa-reviewer
        - principal-investigator

  data-routing-policy:
    require_zero_data_retention: true
    require_in_memory_only: true
    sanitize_before_provider: true
    tokenize_sensitive_fields: true
    allow_internet_egress: false
    local_only_processing: true
    on_no_compliant_provider: block
    log_provider_selection: true

  pii-detector:
    action: redact
    healthcare_mode: true
    detect_patterns:
      - 'SUBJ-[0-9]{6}'
      - 'SITE-[A-Z]{3}-[0-9]{2}'
    redaction:
      marker_format: label
      include_metadata: true
      custom_markers:
        generic_id: "[TRIAL-ID-REDACTED]"

  hipaa-phi-detector:
    action: redact
    mode: hipaa_18
    safe_harbor_method: true

  healthcare-compliance:
    blocked_patterns:
      - prescribe
      - stop taking
      - change the patient dose
    required_disclaimers:
      - This output supports trial operations and is not medical advice.
    fda_class: II

  quality-scorer:
    min_output_chars: 120
    min_sentences: 3
    assertions:
      - type: contains
        name: protocol-reference
        threshold: 1.0
        mode: enforce
        severity: critical
        config:
          value: protocol
    failure_action:
      action: fallback
      fallback_message: Review required because the summary did not meet the configured quality threshold.

  audit-logger: {}

The key point here is not that every trial summary must literally contain the word protocol. It is that quality-scorer lets you encode route-specific expectations instead of trusting polished prose by default. You can tune the assertion to your team's own vocabulary or quality rubric.

Just as important, the example keeps the evidence model honest. audit-logger marks the route as audited. The actual reviewable evidence comes from the decision event stream and export workflows, which means your validation should include those outputs instead of relying on aspirational YAML fields that the policy evaluator does not currently read.

The shortest useful validation loop looks like this:

kt policy lint --file ./clinical-trial-integrity.yaml
kt gateway run --policy-config ./clinical-trial-integrity.yaml --port 41002
kt events tail --policy quality-scorer
kt events export --since 30d --format json --output clinical-trial-events.json

That gives trial and quality teams four concrete checks.

  1. The route configuration is valid.
  2. Non-compliant providers are excluded before routing.
  3. Weak or underspecified summaries are rejected or replaced.
  4. The team can export a real decision trail for review.

Results and impact​

The operational impact is that trial AI stops being a sidecar convenience tool and becomes a governed workflow. Study teams can still move faster on summaries and drafting, but they do so through one policy boundary instead of through whatever assistant happens to be open in a browser tab.

Quality teams also gain a clearer review model. Instead of debating whether an application log is sufficient, they can work from a gateway event stream that records the route decision, policy outcomes, and evidence export path. That makes it easier to answer the kinds of questions regulated studies actually receive: who accessed the route, what identifiers were present, which controls fired, and whether low-quality output was suppressed.

Key takeaways​

  • Clinical trial AI needs output-integrity controls as much as it needs confidentiality controls.
  • audit-logger is a marker in the chain; the broader platform event and export system provides the actual evidence path.
  • Use pii-detector custom regexes to cover study-specific identifiers such as subject or site IDs.
  • Use data-routing-policy to turn compliant-provider rules into runtime enforcement.
  • Use quality-scorer to reject polished but inadequate outputs before they enter a regulated workflow.

Next steps​